Dr. Mark is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
12605 E 16th Ave
# Univ
Aurora, CO 80045Phone+1 720-848-0000
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2005 - 2008
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2002 - 2005
- Stony Brook University Health Sciences Center School of MedicineClass of 2002
- Yale UniversityB.S., Molecular Biophysics and Biochemistry, Cum Laude, 1998
Certifications & Licensure
- CO State Medical License 2016 - 2025
- NY State Medical License 2005 - 2022
- WY State Medical License 2021 - 2022
Awards, Honors, & Recognition
- Named as Super Doctors Rising Star for New York 2015
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
- Clinical Research Training Institute Award American Society of Hematology, 2008
- Join now to see all
Clinical Trials
- Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma Start of enrollment: 2009 Apr 23
- Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study Start of enrollment: 2010 Aug 01
- Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance Start of enrollment: 2011 Oct 28
- Join now to see all
Publications & Presentations
PubMed
- 1081 citationsDaratumumab, Bortezomib, and Dexamethasone for Multiple MyelomaAntonio Palumbo, Asher Chanan-Khan, Katja Weisel, Ajay K. Nooka, Tamás Masszi
The New England Journal of Medicine. 2016-08-24 - 138 citationsImproved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research StudyAnita D'Souza, Angela Dispenzieri, Baldeep Wirk, Mei-Jie Zhang, Jiaxing Huang
Journal of Clinical Oncology. 2015-09-14 - 12 citationsStaging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most ...Emma C. Scott, Parameswaran Hari, Sathish Kumar, Raphael Fraser, Omar Davila
Biology of Blood and Marrow Transplantation. 2018-12-01
Journal Articles
- Autologous/Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Tandem Autologous Transplantation for Multiple Myeloma - Comparison of Long Term Post Relapse Sur...Htut M, D'Souza A, Krishnan A, Bruno B, Zhang MJ, Fei M, Diaz MA, Copelan E, Ganguly S, Hamadani M, Kharfan-Dabaja M, Lazarus H, Lee C, Meehan K, Nishihori T, Saad A, ..., Biol Blood Marrow Transplant, 1/24/2017
- Cellular Proliferation by Multiplex Immunohistochemistry Identifies High Risk Multiple Myeloma in Newly Diagnosed, Treatment Naïve PatientsEly S, Forsberg P, Ousansafi I, Rossi A, Modin A, Pearse R, Pekle K, Perry A, Coleman M, Jayabalan D, Di Liberto M, Chen-Kiang S, Niesvizky R, Mark TM, Clin Lymphoma Myeloma Leuk, 1/20/2017
- Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two PracticesSingh AD, Parmar S, Patel K, Shah S, Shore T, Gergis U, Mayer S, Phillips A, Hsu JM, Niesvizky R, Mark TM, Pearse R, Rossi A, van Besien K, Biol Blood Marrow Transplant, 1/20/2017
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma SamplesTomer M Mark, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Efficacy and Safety of Daratumumab, Bortezomib and Dexamethasone (Dvd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Upda...Weisel K, Lentzsch S, Mateos MV, Hungria V, Munder M, Nooka A, Mark T, Quach H, Scott EC, Lee JJ, Sonneveld P, Casneuf T, Chiu C, Qin X, Amin H, Thiyagarajah P, Schect..., Haematologica; European Hematology Association Meeting, 1/1/2017
- Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Mye...Chari A, Mark TM, Krishnan A, Stockerl-Goldstein K, Usmani SZ, Londhe A, Etheredge D, Parros H, Fleming S, Liu BL, Freeman S, Ukropec J, Lin T, Nooka AK, American Society of Hematology, 1/1/2016
- Join now to see all
Lectures
- Best of Myeloma at ASH 2016.University of Colorado - 1/27/2017
- In the relapsed patient, what would be the ideal treatment?New York, NY - 1/26/2017
- New Drugs in Multiple MyelomaUniversity of Colorado, Anschutz Medical Campus - 1/9/2017
- Join now to see all
Press Mentions
- Oral Triplet Deemed Effective in relapsed/refractory MyelomaMarch 13th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: